Selective antagonism of anticancer drugs for side-effect removal

Area of Science:

• Oncology and Pharmacology
• Molecular Biology
• Cardiovascular Research

Background:

• Kinase inhibitors (KIs) are promising anticancer agents targeting cell proliferation and fate.
• Off-target kinase inhibition can cause toxicity, such as cardiotoxicity, due to cellular context-dependent effects.
• Specific KIs targeting ABL, RAF1, or AMPK can induce pro-apoptotic pathways in cardiomyocytes.

Purpose of the Study:

• To introduce a novel therapeutic strategy termed 'therapeutic editing' to mitigate KI-induced side effects.
• To develop a method where a secondary drug (editor) counteracts the toxicity of a primary KI.
• To ensure overlapping therapeutic impact while suppressing off-target toxicity.

Main Methods:

• Conceptualizing a dual-drug approach combining a primary KI with a 'therapeutic editor' drug.
• Designing the editor drug to specifically interfere with toxicity-related signaling pathways.
• Analyzing the synergistic effects on cancer targets and off-target toxicity.

Main Results:

• The proposed 'therapeutic editing' model demonstrates the potential to suppress off-target toxicity.
• Editor drugs can block downstream propagation of harmful signaling induced by primary KIs.
• This strategy aims to maintain therapeutic efficacy while improving safety profiles.

Conclusions:

• 'Therapeutic editing' offers a promising strategy to enhance the safety of kinase inhibitor cancer therapy.
• By selectively inhibiting toxicity pathways, this approach can reduce adverse events like cardiotoxicity.
• This paradigm shift in drug combination could broaden the clinical application of kinase inhibitors.